Tham khảo Liệu pháp trúng đích

  1. ↑ “Definition of targeted therapy - NCI Dictionary of Cancer Terms”. 
  2. ↑ “Targeted Cancer Therapies”. National Cancer Institute. 
  3. ↑ Syn, Nicholas Li-Xun; Yong, Wei-Peng; Goh, Boon-Cher; Lee, Soo-Chin (ngày 1 tháng 8 năm 2016). “Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review”. Expert Opinion on Drug Metabolism & Toxicology 12 (8): 911–922. ISSN 1744-7607. PMID 27249175. doi:10.1080/17425255.2016.1196187. 
  4. ↑ Perantoni AO, Rice JM, Reed CD, Watatani M, Wenk ML (tháng 9 năm 1987). “Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea”. Proc. Natl. Acad. Sci. U.S.A. 84 (17): 6317–6321. PMC 299062. PMID 3476947. doi:10.1073/pnas.84.17.6317. 

    Drebin JA, Link VC, Weinberg RA, Greene MI (tháng 12 năm 1986). “Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen”. Proc. Natl. Acad. Sci. U.S.A. 83 (23): 9129–9133. PMC 387088. PMID 3466178. doi:10.1073/pnas.83.23.9129. 

    Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI (tháng 7 năm 1985). “Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies”. Cell 41 (3): 697–706. PMID 2860972. doi:10.1016/S0092-8674(85)80050-7. 
  5. ↑ Zhukov NV, Tjulandin SA (tháng 5 năm 2008). “Targeted therapy in the treatment of solid tumors: practice contradicts theory”. Biochemistry Mosc. 73 (5): 605–618. PMID 18605984. doi:10.1134/S000629790805012X. 
  6. ↑ Markman M (2008). “The promise and perils of 'targeted therapy' of advanced ovarian cancer”. Oncology 74 (1–2): 1–6. PMID 18536523. doi:10.1159/000138349. 
  7. ↑ Katzel JA, Fanucchi MP, Li Z (tháng 1 năm 2009). “Recent advances of novel targeted therapy in non-small cell lung cancer”. J Hematol Oncol 2 (1): 2. PMC 2637898. PMID 19159467. doi:10.1186/1756-8722-2-2. 
  8. ↑ Lacroix, Marc (2014). Targeted Therapies in Cancer. Hauppauge, NY: Nova Sciences Publishers. ISBN 978-1-63321-687-7. 
  9. ↑ Jordan VC (tháng 1 năm 2008). “Tamoxifen: catalyst for the change to targeted therapy”. Eur. J. Cancer 44 (1): 30–38. PMC 2566958. PMID 18068350. doi:10.1016/j.ejca.2007.11.002. 
  10. ↑ Warr MR, Shore GC (tháng 12 năm 2008). “Small-molecule Bcl-2 antagonists as targeted therapy in oncology”. Curr Oncol 15 (6): 256–61. PMC 2601021. PMID 19079626. 
  11. ↑ Li J, Zhao X, Chen L và đồng nghiệp (2010). “Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies”. BMC Cancer 10: 529. PMC 2984425. PMID 20923544. doi:10.1186/1471-2407-10-529. 
  12. ↑ “Search of: apatinib - List Results - ClinicalTrials.gov”. clinicaltrials.gov. 
  13. ↑ “Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer.”. 2010. 
  14. ↑ “Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming chemoresistance in glioblastoma”. American Association for Cancer Research. Beibei Zhai, Anna Gobielewska, Anne Steino, Jeffrey A. Bacha, Dennis M. Brown, Simone Niclou and Mads Daugaard. 
  15. ↑ “DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells”. American Association for Cancer Research. Anne Steino, Guangan He, Jeffrey A. Bacha, Dennis M. Brown and Zahid Siddik. 
  16. ↑ “VAL-083 Clinical Trials”. Clinical Trials. GOV. U.S. National Institutes of Health. 
  17. ↑ “Merck, Endocyte in Development Deal”. dddmag.com. Ngày 25 tháng 4 năm 2012. 
  18. ↑ “National Cancer Institute - Keytruda”. 
  19. ↑ “National Cancer Institute - Pembrolizumab Use in Cancer”. 
  20. ↑ “Therascreen KRAS RGQ PCR Kit – P110030“. Device Approvals and Clearances. U.S. Food and Drug Administration. 2012-07-06.
  21. ↑ European medicines Agency (June 2014). “Erbitux® Summary of Product Characteristics (PDF).“ 2015-11-19.
  22. ↑ “Cetuximab (Erbitux). About the Center of Drug Evaluation and Research." U.S. Food and Drug Administration. 2015-11-16.
  23. ↑ "Merck KGaA: European Commission Approves Erbitux for First-Line Use in Head and Neck Cancer" 2015-11-16
  24. ↑ Pollack, Andrew (ngày 31 tháng 3 năm 2009). “F.D.A. Panel Supports Avastin to Treat Brain Tumor”. New York Times. Truy cập ngày 13 tháng 8 năm 2009. 

Liên quan

Tài liệu tham khảo

WikiPedia: Liệu pháp trúng đích http://www.cancerdriver.com/ http://www.current-oncology.com/index.php/oncology... http://www.dddmag.com/news/2012/04/merck-endocyte-... //www.merck.de/de/presse/extNewsDetail.html?newsId... http://www.bbm1.ucm.es/cannabis/publicaciones_es.h... //www.ema.europa.eu/docs/en_GB/document_library/EP... http://www.cancer.gov/cancertopics/factsheet/Thera... http://www.cancer.gov/dictionary?cdrid=270742 http://clinicaltrials.gov/ct2/results?term=apatini... http://www.fda.gov/AboutFDA/CentersOffices/Officeo...